These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 20112428)

  • 1. Enantiotropically related albendazole polymorphs.
    Pranzo MB; Cruickshank D; Coruzzi M; Caira MR; Bettini R
    J Pharm Sci; 2010 Sep; 99(9):3731-42. PubMed ID: 20112428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of albendazole crystallization in poly(vinylpyrrolidone) solid molecular dispersions.
    Kalaiselvan R; Mohanta GP; Manna PK; Manavalan R
    Pharmazie; 2006 Jul; 61(7):618-24. PubMed ID: 16889070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solid-state properties and crystallization behavior of PHA-739521 polymorphs.
    Sun CC
    Int J Pharm; 2006 Aug; 319(1-2):114-20. PubMed ID: 16720086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (13)C and (15)N solid-state NMR studies on albendazole and cyclodextrin albendazole complexes.
    Ferreira MJ; García A; Leonardi D; Salomon CJ; Lamas MC; Nunes TG
    Carbohydr Polym; 2015 Jun; 123():130-5. PubMed ID: 25843843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enantiotropically-related polymorphs of {4-(4-chloro-3-fluorophenyl)-2-[4-(methyloxy)phenyl]-1,3-thiazol-5-yl} acetic acid: crystal structures and multinuclear solid-state NMR.
    Vogt FG; Katrincic LM; Long ST; Mueller RL; Carlton RA; Sun YT; Johnson MN; Copley RC; Light ME
    J Pharm Sci; 2008 Nov; 97(11):4756-82. PubMed ID: 18300300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-solvent polymorph screen of carbamazepine.
    Getsoian A; Lodaya RM; Blackburn AC
    Int J Pharm; 2008 Feb; 348(1-2):3-9. PubMed ID: 17945448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of the phase diagrams of chiral praziquantel.
    Liu Y; Wang X; Wang JK; Ching CB
    Chirality; 2006 May; 18(4):259-64. PubMed ID: 16521119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization and selective crystallization of famotidine polymorphs.
    Lu J; Wang XJ; Yang X; Ching CB
    J Pharm Sci; 2007 Sep; 96(9):2457-68. PubMed ID: 17518361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformational polymorphism in aripiprazole: Preparation, stability and structure of five modifications.
    Braun DE; Gelbrich T; Kahlenberg V; Tessadri R; Wieser J; Griesser UJ
    J Pharm Sci; 2009 Jun; 98(6):2010-26. PubMed ID: 19009597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triclabendazole: an intriguing case of co-existence of conformational and tautomeric polymorphism.
    Tothadi S; Bhogala BR; Gorantla AR; Thakur TS; Jetti RK; Desiraju GR
    Chem Asian J; 2012 Feb; 7(2):330-42. PubMed ID: 22147668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving Properties of Albendazole Desmotropes by Supramolecular Systems with Maltodextrin and Glutamic Acid.
    Bongioanni A; Araújo BS; de Oliveira YS; Longhi MR; Ayala A; Garnero C
    AAPS PharmSciTech; 2018 Apr; 19(3):1468-1476. PubMed ID: 29464593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystallization, spectral, crystallographical, and thermoanalytical studies of succinobucol polymorphism.
    Jurček O; Lahtinen M; Wimmer Z; Drašar P; Kolehmainen E
    J Pharm Sci; 2012 May; 101(5):1794-802. PubMed ID: 22323097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization, selection, and development of an orally dosed drug polymorph from an enantiotropically related system.
    Katrincic LM; Sun YT; Carlton RA; Diederich AM; Mueller RL; Vogt FG
    Int J Pharm; 2009 Jan; 366(1-2):1-13. PubMed ID: 18824090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase transformation in conformational polymorphs of nimesulide.
    Sanphui P; Sarma B; Nangia A
    J Pharm Sci; 2011 Jun; 100(6):2287-99. PubMed ID: 21491446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of nicergoline polymorphs crystallized in several organic solvents.
    Malaj L; Censi R; Capsoni D; Pellegrino L; Bini M; Ferrari S; Gobetto R; Massarotti V; Di Martino P
    J Pharm Sci; 2011 Jul; 100(7):2610-22. PubMed ID: 21254066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salt screening and characterization for poorly soluble, weak basic compounds: case study albendazole.
    Paulekuhn GS; Dressman JB; Saal C
    Pharmazie; 2013 Jul; 68(7):555-64. PubMed ID: 23923637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Didanosine polymorphism in a supercritical antisolvent process.
    Bettini R; Menabeni R; Tozzi R; Pranzo MB; Pasquali I; Chierotti MR; Gobetto R; Pellegrino L
    J Pharm Sci; 2010 Apr; 99(4):1855-70. PubMed ID: 19827134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A computationally inspired investigation of the solid forms of (R)-1-phenylethylammonium-(S)-2-phenylbutyrate.
    Antoniadis CD; D'Oria E; Karamertzanis PG; Tocher DA; Florence AJ; Price SL; Jones AG
    Chirality; 2010 May; 22(4):447-55. PubMed ID: 19644934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solid-state characterization of chlordiazepoxide polymorphs.
    Singh D; Marshall PV; Shields L; York P
    J Pharm Sci; 1998 May; 87(5):655-62. PubMed ID: 9572919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variable-temperature X-ray powder diffraction analysis of the crystal transformation of the pharmaceutically preferred polymorph C of mebendazole.
    de Villiers MM; Terblanche RJ; Liebenberg W; Swanepoel E; Dekker TG; Song M
    J Pharm Biomed Anal; 2005 Jul; 38(3):435-41. PubMed ID: 15925244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.